Analytical Tools & Diagnostic Assays
Combining our aptamer design expertise with novel assays and devices, AuramerBio provides customisable sensing solutions for medical and environmental research, and beyond.
Our team's expertise with small molecule targets, is illustrated by our growing catalogue of gold standard hormone binding aptamers.
Using our proprietary selection and optimisation methods we can produce industry leading DNA aptamers to bind the target of your choice. Once an aptamer has been developed we also offer a service to optimise its performance on a range of assay platforms.
We have a growing catalogue of DNA aptamers available to purchase for research and evaluation. If the target you are interested in is not shown please contact us as we have a number of other targets in development.
Estradiol (Kd 27.8 ± 10.7 nM)
Progesterone (Kd 64.5 ± 31.2 nM)
Testosterone (Kd 33.8 ± 14.5 nM)
Androstenedione (Kd 15.3 ± 6.5 nM)
Bisphenol A (BPA) (Kd 7.4 ± 2.6 nM)
All of our aptamers are available as AptaGold assay kits, please contact us for further information.
We are also developing a number of proprietary assay platforms including an electrochemical aptasensor capable of quantifying Estradiol at sub-femto grams per ml in biological samples (Urine and Blood).
The AuramerBio Team
Our team has a wide skill-base positioning us perfectly to rapidly deploy aptamers into a range of analytical assay and device platforms.
dr Shalen kumar
Founding inventor of our technology platform and SELEX expert, Dr Kumar has over 10 years experience in the development of aptamers and integration in various sensing platforms. Dr Kumar heads the team and the technical development of products and partnership management.
Dr Peter Li
Dr Li has over 10 years of experience in aptamer research with a background in chemistry. Dr Li brings a wealth of experience in chemical conjugation, aptamer selection and characterisation strategies. Dr Li has also developed several aptamer based assay formats. Dr Li heads the R&D for product development.
Dr Kelly Campen
Dr Campen has been part of the reproductive biotechnology research team for 10 years. After 3 years postdoc in the US, Dr Campen returned with a wealth of molecular biology experience and now leads the Custom Service Development side of Auramers business and customer relations.
Prof Ken McNatty
Professor McNatty is a highly decorated internationally recognised scientist within the fertility field. Prof McNatty’s passion and vision for innovative science project led to the foundation of aptamer research in New Zealand. During his research career, Prof McNatty has published over 300 scientific publications in peer reviewed journals, whilst also being an inventor in over 10 patents. Prof McNatty’s experience with commercialisation (AndroVax®) has been key in guiding the science team.
Dr Janet Pitman
Dr Pitman has a wealth of knowledge in the reproductive biology and molecular diagnostics field. Dr Pitman has developed a number of ultrasensitive real time PCR assays critical for identifying key markers that indicate the fertility status. Dr Pitman works closely with the Science team on daily basis and oversees the management of the lab.
The AuramerBio directors
Director & Chair
Graeme has over 25 years of senior executive experience in the private sector and New Zealand government public sector. He is currently Chair and/or Board Member/Director of 8 companies in NZ and Australia. Not only does he bring his extensive governance and executive management experience to AuramerBio but also many years of experience as a clinical biochemist in the NZ health and biotechnology sectors.
John's passion for technical innovation, customer relationships and commercial enterprise has been applied to a number of roles across the commercial sector including chemical, oil, technology and telecommunications. He has over 15 years senior leadership experience in business and technology. Currently John oversees all of ESR’s forensic business group activities.
Geoff has extensive experience in raising capital, buying and selling technology businesses, formulating joint venture agreements and adding significant commercial value to technology projects. He is currently Managing Director of Viclink, serves on a number of technology and medical companies, and is a core participant in a start-up medical device company.
Melissa is highly experienced in healthcare commercialisation in both the private and public sectors. Her investment track record has resulted in excess of $30M raised for NZ technology companies. An alumna of the Entrepreneur Programme at MIT, Melissa has held executive roles in technology start-ups since 2012, leading strategic growth, establishing international sales and negotiating key partnerships.